Dr. Todd Bertoch, M.D.
Anesthesiology (Anesthesiology Physician)
1003 Willow Creek Rd
Prescott, AZ 86301
Who else practices at this address →
Yavapai County includes primary care (56% of residents) and dental (14% of residents) and mental health (50% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Anesthesiology Physician primary
AZ license 35064
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 23 payments worth $19,259 in total to this clinician.
| Vertex Pharmaceuticals Incorporated | $17,339 |
|---|---|
| Merck Sharp & Dohme LLC | $1,920 |
| Consulting Fee | $9,355 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $6,550 |
| Travel and Lodging | $3,064 |
| Food and Beverage | $289 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Vertex Pharmaceuticals Incorporated May 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,550 |
| Vertex Pharmaceuticals Incorporated Apr 9, 2025 | Consulting Fee | $5,635 |
| Vertex Pharmaceuticals Incorporated Feb 19, 2025 | Consulting Fee | $1,800 |
| Vertex Pharmaceuticals Incorporated Mar 9, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $1,001 |
| Merck Sharp & Dohme LLC Sep 22, 2025 | Consulting FeeCompany’s descriptionProvided as part of a clinical research engagement. | $960 |
| Merck Sharp & Dohme LLC Dec 15, 2025 | Consulting Fee NEUROSCIENCE Company’s descriptionProvided as part of a clinical research engagement. | $960 |
| Vertex Pharmaceuticals Incorporated Feb 17, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $951 |
| Vertex Pharmaceuticals Incorporated Mar 10, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $348 |
| Vertex Pharmaceuticals Incorporated Feb 18, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $278 |
| Vertex Pharmaceuticals Incorporated Feb 18, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $159 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 15, 2025 | Consulting Fee NEUROSCIENCE Company’s descriptionProvided as part of a clinical research engagement. | $960 |
| Merck Sharp & Dohme LLC Sep 22, 2025 | Consulting FeeCompany’s descriptionProvided as part of a clinical research engagement. | $960 |
| Vertex Pharmaceuticals Incorporated May 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,550 |
| Vertex Pharmaceuticals Incorporated Apr 9, 2025 | Consulting Fee | $5,635 |
| Vertex Pharmaceuticals Incorporated Apr 9, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $35.12 |
| Vertex Pharmaceuticals Incorporated Mar 10, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $348 |
| Vertex Pharmaceuticals Incorporated Mar 10, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $84.70 |
| Vertex Pharmaceuticals Incorporated Mar 10, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $74.54 |
| Vertex Pharmaceuticals Incorporated Mar 9, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $1,001 |
| Vertex Pharmaceuticals Incorporated Feb 19, 2025 | Consulting Fee | $1,800 |
| Vertex Pharmaceuticals Incorporated Feb 18, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $278 |
| Vertex Pharmaceuticals Incorporated Feb 18, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $159 |
| Vertex Pharmaceuticals Incorporated Feb 18, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $132 |
| Vertex Pharmaceuticals Incorporated Feb 17, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $951 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 9 companies. The companies reported $3,240,849 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Randomized, Double-blind, Placebo controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
Vertex Pharmaceuticals Incorporated - A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - TRIPHA TRN-228-302_Bunion_P3
Tris Pharma Inc - A Phase 3b, Open-label, Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine As Part of Multimodal Therapy for Acute Pain After Aesthetic or Reconstructive Surgeries
Vertex Pharmaceuticals Incorporated - A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
ModernaTX, Inc. · Completed · NCT05575492 - Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
Sanofi Pasteur Inc. · Completed · NCT06641180 - A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees
American Regent · Completed · NCT01925261 - Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
ModernaTX, Inc. · Completed · NCT05992935 - A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
Sanofi Pasteur Inc. · Completed · NCT06361875
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.